BRCA1 and breast carcinoma: Furthermore, the administration of STING reinstated the BRCA1-deficient breast cancer’s sensitivity to the PARP inhibitor.600 In certain tumors characterized by DNA repair deficiencies, the therapeutic efficacy of this combination can be further magnified.